Phase 1/2Recruiting
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 in Patients With Selected Advanced Solid Tumors
- Sponsor
- AskGene Pharma, Inc. (Industry)
- Enrollment
- 594 planned
- Conditions
- Advanced Solid Tumors
- Interventions
- ASKG915; Paclitaxel + Bevacizumab; Fruquintinib; Docetaxel
- Ages
- adults, older adults
- Registry
- NCT05867420
Full record on ClinicalTrials.gov
From the registry
The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.
Primary outcomes
- Dose limiting toxicities (DLTs)
- Adverse events(AEs)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered